RECITE: A Phase 3 Randomized Placebocontrolled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving FOLFOX-based Chemotherapy for Treatment of Gastrointestinal or Colorectal Cancer
Phase of Trial: Phase III
Latest Information Update: 10 Dec 2019
Price : $35 *
At a glance
- Drugs Romiplostim (Primary)
- Indications Thrombocytopenia
- Focus Registrational; Therapeutic Use
- Sponsors Amgen
- 21 Oct 2019 Planned End Date changed from 2 Oct 2022 to 18 Sep 2022.
- 21 Oct 2019 Planned primary completion date changed from 31 Oct 2021 to 17 Oct 2021.
- 26 Sep 2019 Status changed from not yet recruiting to recruiting.